Adverse Event Reporting of Four Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies for Migraine Prevention: A Real-World Study Based on the FDA Adverse Event Reporting System
January 2024
in “
Frontiers in Pharmacology
”
TLDR These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.
This study analyzed adverse event (AE) reports for four anti-Calcitonin gene-related peptide monoclonal antibodies (erenumab, galcanezumab, fremanezumab, and eptinezumab) used for migraine prevention, using data from the FDA Adverse Event Reporting System from 2018 to 2023. A total of 65,792 reports were reviewed, revealing common AEs such as constipation and alopecia for erenumab, injection site reactions for galcanezumab and fremanezumab, and fatigue for eptinezumab. Additionally, new AEs not listed in drug instructions, like Raynaud's phenomenon and weight increase, were identified. These findings provide valuable insights into the safety profiles of these medications for clinical use.
